Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses

Inflammopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Language: Английский

---

Efficacy, safety and mechanistic insights of pentoxifylline in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 22, 2025

Abstract Novel treatments that act beyond the conventionally targeted monoamine system are urgently needed to provide more effective relief for patients with major depressive disorder. Pentoxifylline (PTX) is a phosphodiesterase inhibitor potent anti-inflammatory and antioxidant effects, additional pleiotropic effects. This first systematic review meta-analysis examine role of PTX in A comprehensive search electronic databases, including PubMed, Scopus, Cochrane, Web Science, was performed October 2024. We included only randomized controlled trials (RCTs), their data were extracted analyzed using Reman 5.4 software. The primary outcome change Hamilton Depression Rating Scale (HAM-D). Four RCTs 318 study. showed statistically significant improvement HAM-D scores at endpoint compared placebo (MD = –3.84, 95% CI [–4.87 –2.81], P < 0.00001). Moreover, increase serotonin BDNF levels 20.76 ng/mL, [5.49 36.04], 0.008; MD 10.83 [-0.22 21.88], 0.05, respectively) decrease TNF-α IL-6 –3.24 pg/mL, [–4.12 –2.36], 0.00001; –2.64 pig/mL, [–3.79 –1.48], 0.00001, respectively). There no difference between any reported side study findings suggest may be safe as an adjuvant antidepressant agent MDD, demonstrating reduction scores. results this need interpreted caution considering several limitations.

Language: Английский

---

Efficacy of pentoxifylline for the treatment of bipolar I/II patients with treatment-resistant depression: A proof-of-concept, randomized, double-blind, placebo-controlled trial

Brain Research Bulletin, Journal Year: 2024, Volume and Issue: 216, P. 111047 - 111047

Published: Aug. 10, 2024

Immune dysregulation can play a role in depression pathophysiology, and immunological antagonists improve depressive symptoms treatment-resistant bipolar (TRD) patients according to studies. To evaluate the anti-depressant effects of anti-inflammatory drug, pentoxifylline (PTX) TRD I/II adult subjects. This 12-week, randomized, double-blind, placebo-controlled, parallel-group trial 60 participants was conducted at Hawler Psychiatric Hospital Private Clinic Erbil, Iraq. Participants were confirmed as being qualified for based on DSM-5 criteria. Data analyzed using modified intent-to-treat analysis. There no significant differences between two groups Hamilton Rating Scale Depression-17 (HAM-D-17) scores (χ2=1.9, P =.48) or time × treatment interaction (χ2=7.1, P=.54). Nevertheless, effect observed with both groups' reduction HAM-D-17 from start endpoint (χ2= 2.11, P=.002). Besides, CRP found (χ2=3.1, P=0.016), where there more score PTX-treated subjects CRP> 7.1 mg/L. The response rate difference PTX placebo group did not reach significance level (χ2=0.84, p=0.43). Furthermore, serum concentrations TNF-α, CRP, IL-6 significantly reduced week 12 (P=.007,.04, <.001, respectively). current proof concept study that terms overall effectiveness TRD, is superior placebo. However, it may mood subpopulation higher pretreatment inflammatory profile.

Language: Английский

---

The efficacy of pentoxifylline for major depressive disorder

Wiener klinische Wochenschrift, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

Language: Английский

---

Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 156, P. 114689 - 114689

Published: April 19, 2025

Language: Английский

---

Pentoxifylline Prevents Neuroinflammation and Modifies PTEN/TrkB Signaling in an LPS-Induced Depression Model

Journal of Neuroimmune Pharmacology, Journal Year: 2025, Volume and Issue: 20(1)

Published: April 3, 2025

Language: Английский

---

Impact of Chronic Stress on Intestinal Mucosal Immunity in Colorectal Cancer Progression

Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---

How to Improve Methodological Issues in Clinical Trials to Confirm that Pentoxifylline is Useful as an Add-on Therapy for Major Depressive Disorder

Pharmacopsychiatry, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

The article authored by Mohammad et al. [1], published in Pharmacopsychiatry July 2024, presents preliminary evidence on the impact of pentoxifylline (PTX) alleviating depressive symptoms, improving patients' quality life, and assessing potential adverse effects. Investigating this novel therapeutic approach is essential for broadening treatment options available to patients with major disorder (MDD) advancing strategies manage complex condition. However, certain aspects study require careful consideration strengthen findings facilitate more comprehensive discussions future research.

Language: Английский

---

Pentoxifylline in COVID-19 and considerations for its research in long COVID

Inflammation Research, Journal Year: 2024, Volume and Issue: 73(12), P. 2057 - 2068

Published: Oct. 24, 2024

Pentoxifylline (PTX) affects most blood components and the vessels, potentially modulating various conditions. Due to its impact on markers linked COVID-19 severity, research has explored PTX for acute COVID-19. Following widespread administration of vaccinations, there been a notable consistently growing increase in focusing long COVID. Consequently, our examination relevant data shall additionally be contextualized into COVID research.

Language: Английский

---